Home / Indicators / Cancer medicine spending vs Sales growth at constant exchange rates Cancer medicine spending vs Sales growth at constant exchange rates Cancer medicine spending and Sales growth at constant exchange rates worldwide, compared over time.
Change the pair
Compare different indicators
The series
Over time Global, spaced by time
. Different units, drawn on separate scales and clipped to the years both
series publish — earlier history stays on each indicator's own page.
Read the values, not the heights.
Cancer medicine spending
Unit: billion USD · 2 observations
Line chart
Cancer medicine spending Cancer medicine spending. 2 observations from 2024 to 2029, ranging from 252 billion USD to 441 billion USD, of which 1 are forecasts. Latest value 441 billion USD (2029).
billion USD
0
100
200
300
400
500
2024
2025
2026
2027
2028
2029
FORECAST
252
441
Cancer medicine spending Cancer medicine spending. 2 observations from 2024 to 2029, ranging from 252 billion USD to 441 billion USD, of which 1 are forecasts. Latest value 441 billion USD (2029).
billion USD
0
100
200
300
400
500
2024
2025
2026
2027
2028
2029
FORECAST
252
441
Cancer medicine spending Cancer medicine spending. 2 observations from 2024 to 2029, ranging from 252 billion USD to 441 billion USD, of which 1 are forecasts. Latest value 441 billion USD (2029).
billion USD
0
100
200
300
400
500
2024
2025
2026
2027
2028
2029
FORECAST
252
441
View the underlying data Sales growth at constant exchange rates
Unit: % · 2 observations
Line chart Sales growth at constant exchange rates Sales growth at constant exchange rates. 2 observations from Q1 2026 to Q2 2026, ranging from 3% to 17.8%. Latest value 17.8% (Q2 2026).
%
0
5
10
15
20
2024
2025
2026
2027
2028
2029
3%
18%
Sales growth at constant exchange rates Sales growth at constant exchange rates. 2 observations from Q1 2026 to Q2 2026, ranging from 3% to 17.8%. Latest value 17.8% (Q2 2026).
%
0
5
10
15
20
2024
2025
2026
2027
2028
2029
3%
18%
Sales growth at constant exchange rates Sales growth at constant exchange rates. 2 observations from Q1 2026 to Q2 2026, ranging from 3% to 17.8%. Latest value 17.8% (Q2 2026).
%
0
5
10
15
20
2024
2025
2026
2027
2028
2029
3%
18%
View the underlying data Provenance
Where these numbers come from Total expenditure on oncology medicines measured at invoice or list prices.
2 observations in Global · source
organisations: IQVIA
Percentage change in sales calculated at constant exchange rates over the specified period.
2 observations in Global · source
organisations: Roche, Sanofi
Data published under CC BY 4.0 .
Series A as JSON · Series B as JSON